ArQule, Inc. (NASDAQ
ARQ 531 better than Calquence and Imbrivica
Paolo Pucci the CEO ArQule gave the update during
The success of ARQ531 is a significant milestone because close to 80% of patients with chronic lymphocytic leukemia usually become resistant to drugs such as Imbruvica and Calquence. ARQ531 makes a difference in that it does not irreversibly bind to a target like BTK inhibitor Imbruvica. It appears like the anecdotal result could make a significant difference to the patient population.
Imbruvica is marketed by AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) as partners and they reported sales $6.2 billion last year. At least four-fifths of the patients using Imbruvica develop mutant resistance which does not stop ARQ 531.
Find out when $ARQL reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
ArQule banks on the success of ARQ 531
This continued success is a great opportunity for ArQule who have recently seen their market cap rise to $544 million which is quite inexpensive considering its pipeline. If ARQ 531 continues to be successful without any safety concerns then ARQL stock will continue to grow. ARQ 531 is among the clinical stage drugs that the company is developing that are in the pre-commercial stage.
Although ARQ 531 has potential development of cancer drugs can be somewhat brutal. Much is not known about the drug yet which is not encouraging. Derazantinib is the most advanced asset of ArQule and there is also
Sign-up for continuing coverage on shares of $ARQL stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $ARQL, either long or short, and we have not been compensated for this article.